Funded Project Details - FY2021
|Title:|| Role of SIRT3 in melanoma development and progression|
|Congressional District Code:
||Clinical Science R&D
|| April 2017 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Melanoma, one of the deadliest cancer of skin, arises from melanocytic cells that are responsible for melanin production. Recent advances in the understanding of melanoma biology has led to the development of targeted therapies with promise. For example, BRAF inhibitors vemurafenib and dabrafenib achieved significant improvement over chemotherapy and were approved for metastatic melanomas with BRAF- mutations. More recently, the combination of dabrafenib with MEK inhibitor trametinib demonstrate...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.